A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders

NCT02125318 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Thrombocytosis
Myeloproliferative Neoplasms

Interventions

DRUG: Anagrelide CR

Sponsor

Galena Biopharma, Inc.